SM
PACB icon

Sciencast Management’s Pacific Biosciences PACB Stock Holding History

Sciencast Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-54,173
Closed -$461K – 601
2022
Q1 		$461K Buy
54,173
+25,255
+87% +$291K 0.11% 246
2021
Q4 		$543K Buy
+28,918
New +$698K 0.1% 272

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sciencast Management's PACB Position: Q2 2022 in Review

Sciencast Management sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 54,173 shares — an estimated $461K sold.

Sciencast Management first reported a position in PACB in Q4 2021 and held it in 2 quarters. The position peaked at $543K in Q4 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Sciencast Management reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Sciencast Management sold 54,173 Pacific Biosciences shares in Q2 2022, an estimated $461K.
  • Sciencast Management first reported a position in Pacific Biosciences in Q4 2021 and held it in 2 quarters.
  • Sciencast Management's Pacific Biosciences position peaked at $543K in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.